Company:  DYAX CORP (DYAX)
Form Type:  8-K
Filing Date:  3/29/2013 
CIK:  0000907562 
Address:  55 NETWORK DRIVE 
City, State, Zip:  BURLINGTON, Massachusetts 01803-2756 
Telephone:  617-250-5769 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$6.91  
Change: 
0.065 (0.95%)  
Trade Time: 
Apr 24  
Market Cap: 
$937.55M
Description of Business
The principal focus of our efforts is to develop and commercialize treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. We developed KALBITOR on our own, and since 2010, we have been selling it in the United States for the treatment of acute attacks of HAE. We are also developing DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein, which we believe is a candidate to treat HAE prophylactically. The safety, tolerability, and kallikrein inhibition results of a Phase 1a clinical study in healthy volunteers support advancing the DX-2930 development program into a Phase 1b study in HAE patients in mid-2014. We have also completed development of a biomarker assay that should assist us in detecting the activation of plasma kallikrein in patient blood.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 5 CORPORATE GOVERNANCE
      Item 5.02 Departure of Directors or Certain Officers; ...
    SECTION 8 OTHER EVENTS
      Item 8.01 Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURE
    EXHIBIT INDEX
  EXHIBIT 10.1
  EXHIBIT 10.2
  EXHIBIT 10.3
  EXHIBIT 10.4
BROKERAGE PARTNERS